Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 74

recruiting
3 972
countries
28
conditions
2 103

1 070 trials match your criteria

Non-small cell lung cancer stage IV

Not recruiting

Study of Sotorasib Treatment for First-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Sotorasib

B-cell lymphoma+2

Not recruiting

Study on Lisocabtagene Maraleucel for Adults with Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Lisocabtagene Maraleucel

Small cell lung cancer limited stage

Not recruiting

Study of Tarlatamab for Patients with Limited-Stage Small-Cell Lung Cancer After Chemoradiotherapy

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Argipressin

Non-small cell lung cancer

Not recruiting

Study of Datopotamab Deruxtecan, Durvalumab, and Carboplatin for Advanced Non-Small Cell Lung Cancer in Patients Without Actionable Genomic Alterations

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Breast cancer

Not recruiting

Study on Adding Capecitabine to Carboplatin-Based Chemotherapy for Patients with Early Triple Negative Breast Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

B-cell small lymphocytic lymphoma

Not recruiting

Study Comparing Zanubrutinib with Bendamustine and Rituximab for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab

Relapsing-remitting multiple sclerosis

Not recruiting

Study comparing stem cell transplantation versus alemtuzumab, cladribine or ocrelizumab in patients with aggressive relapsing-remitting multiple sclerosis

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Alemtuzumab

Acute myocardial infarction

Not recruiting

Study on Ticagrelor for Patients with Heart Attack After Coronary Stenting

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Ticagrelor

Paroxysmal nocturnal haemoglobinuria

Not recruiting

Study Comparing Crovalimab and Eculizumab for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently on Complement Inhibitors

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Crovalimab

Chronic lymphocytic leukaemia

Not recruiting

Study of pirtobrutinib, venetoclax and rituximab combination compared to venetoclax and rituximab in previously treated Chronic Lymphocytic Leukemia patients

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib

Transitional cell carcinoma

Not recruiting

Study of Disitamab Vedotin and Pembrolizumab for Patients with Untreated Advanced Urothelial Cancer Expressing HER2

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Chronic lymphocytic leukaemia

Not recruiting

Study on Acalabrutinib and Venetoclax for Newly Diagnosed Chronic Lymphocytic Leukemia Patients at High Risk of Infection and Early Treatment Needs

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.